ResMed overview

ResMed (NYSE: RMD and ASX: RMD.AX) is a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the p​otentially serious health consequences of untreated sleep-disordered breathing.

The ResMed story

When ResMed was formed in 1989, its primary purpose was to commercialize a device for treating obstructive sleep apnea (OSA), a major subset of SDB. Developed in 1981 by Professor Colin Sullivan and colleagues at the University of Sydney, nasal continuous positive airway pressure (CPAP) provided the first successful noninvasive treatment of OSA. Since 1989, ResMed has maintained its focus on SDB, which is gaining greater public and physician awareness. Operations have grown dramatically through the introduction of a number of highly innovative product lines.

The market

SDB affects around 20% of the adult population¹, making it as widespread as diabetes or asthma. However, awareness is low and we believe that about 90% of people who have OSA remain undiagnosed and untreated. Along with an increasing understanding of the morbidity and mortality caused by SDB, this discrepancy has created one of the fastest growing segments of the respiratory industry. ResMed is positioned to meet the growing challenges of this under-penetrated market.

1 Young et al. Am J Respir Crit Care Med. 2002; 165:1217-1239

Increasing awareness

ResMed is committed to increasing education and awareness of the serious health consequences of untreated SDB among both the general public and physicians. Our extensive geographical coverage allows us to work progressively towards this awareness. We have established ResMed Foundations in both Australia and the United States and are funding a primary care physician program (together with other industry participants) to educate doctors on the dangers of undiagnosed SDB.

Continue reading about understanding SDB, ResMed treatment, continuing research and product development.​